Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate

Urology

Volumn 55, Issue 2, 2000, Pages 169-174

  Deweese, Theodore L ^a   Song, Danny Y ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ADVANCED CANCER; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW;

EID: 0033973235     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00419-7     Document Type: Short Survey

References (35)

1. Kaufman D.S., Shipley W.U., Griffin P.P., et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 329:1993;1377-1382.
2. Herskovic A., Martz K., al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1992;1593-1598.
3. Nigro N.D. An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum. 27:1984;763-766.
4. Huggins C., Hodges C.V. Studies on prostate cancer effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate . Cancer Res. 1:1941;293-297.
5. Del Regato J: Radiotherapy for carcinoma of the prostate. A report from the Committee for the Cooperative Study of Radiotherapy for Carcinoma of the Prostate. Colorado Springs, Penrose Cancer Hospital, 1968.
6. Green N., Bodner H., Broth E., et al. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys. 10:1984;971-976.
7. Neglia W.J., Hussey D.H., Johnson D.E. Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2:1977;873-882.
8. Van Der Werf-Messing B., Sourek-Zikova V., Blonk D.I. Localized advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1:1976;1043-1048.
9. Lawton C, Winter K, Murray K, et al: Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate (abstract). Proc ASCO 18: 311a, 1999.
10. Zagars G.K., Johnson D.E., von Eschenbach A.C., et al. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate long-term results of a prospective randomized study . Int J Radiat Oncol Biol Phys. 14:1988;1085-1091.
11. Granfors T., Modig H., Damber J.E., et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement a prospective randomized study . J Urol. 159:1998;2030-2034.
12. Mukamel E., Servadio C., Lurie H. Combined external radiotherapy and hormonal therapy for localized carcinoma of the prostate. Prostate. 4:1983;283-287.
13. Pilepich M.V., Krall J.M., Johnson R.J., et al. Prognostic factors in carcinoma of the prostate - analysis of the RTOG 75-06. Int J Radiat Oncol Biol Phys. 13:1987;339-349.
14. Pilepich M.V., Krall J.M., John M.J., et al. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy preliminary results of RTOG 83-07 . Int J Radiat Oncol Biol Phys. 16:1989;813-817.
15. Pilepich M.V., John M.J., Krall J.M., et al. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol. 13:1990;461-464.
16. Pilepich M.V., Krall J.M., al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma a randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
17. Pilepich MV, Winter K, Roach M, et al: Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate (abstract). Int J Radiat Oncol Biol Phys 42: 177, 1998.
18. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
19. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
20. Bolla M, Collette L, Warde P, et al: Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study (abstract). Int J Radiat Oncol Biol Phys 45: 147, 1999.
21. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol. 155:1996;213-219.
22. Sneller Z.W., Hop W.C.J., Carpentier P.J., et al. Prognosis and prostatic volume changes during endocrine management of prostate cancer a longitudinal study . J Urol. 147:1992;962-966.
23. Anderson P.R., Hanlon A.L., Movsas B., et al. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys. 39:1997;1025-1030.
24. D'Amico A., Whittington R., Malkowicz S., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
25. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analyses of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 280:1998;975-980.
26. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer a randomised trial . Lancet. 353:1999;267-272.
27. Zelefsky M.J., Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer reducing the potential morbidity of therapy . Urology. 49:1997;38-45.
28. Forman J.D., Kumar R., Haas G., et al. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate effects on the volume of normal tissue irradiation . Cancer Invest. 13:1995;8-15.
29. Yang F.E., Chen G.T.Y., Ray P., et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys. 33:1995;1009-1017.
30. DeWeese T.L., Shipman J.M., Dillehay L.E., et al. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol. 159:1998;591-598.
31. Furuya Y., Lin X.S., Walsh J.C., et al. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology. 136:1995;1898-1906.
32. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 28:1996;251-265.
33. Zietman A.L., Nakfoor B.M., Prince E.A., et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor an in vitro and in vivo study . Cancer J Sci Am. 3:1997;31-36.
34. Joon D.L., Hasegawa M., Sikes C., et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 38:1997;1071-1077.
35. Schroder F.H. Endocrine treatment of prostate cancer - recent developments and the future. Part I: maximal androgen blockade, early vs delayed endocrine treatment and side-effects . Br J Urol. 83:1999;161-170.